ALMR
NASDAQAlamar Biosciences Inc.
Price$26.12+0.50 (+1.95%)
02:15 PM07:45 PM
News · 26 weeks33+500%
2026-01-252026-07-19
Mix1790d
- Other6(35%)
- Analyst5(29%)
- SEC Filings3(18%)
- Earnings2(12%)
- Offering1(6%)
Latest news
25 items- SECSEC Form 8-K filed by Alamar Biosciences Inc.8-K - Alamar Biosciences, Inc. (0002104204) (Filer)
- PRAlamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event. About Alamar Biosciences Alamar is a commercial-stage proteomics company est
- PRAlamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative DiseasesFremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a partnership with leading research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s D
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.SCHEDULE 13D/A - Alamar Biosciences, Inc. (0002104204) (Subject)
- PRAlamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease ResearchFremont, CA, July 07, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplexed panel kits, immediately deployable on the entire installed base of ARGO™ HT instruments, and as a single-plex assay through the company’s Technology Access Program (TAP). The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer
- SECSEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.SCHEDULE 13G - Alamar Biosciences, Inc. (0002104204) (Subject)
- PRAlamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex ProteomicsFremont, CA, June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. "This launch reflects our commitment to making proteomics more accessible for population-based screening programs," said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. "By comb
- ANALYSTAnalyst initiated coverage on Alamar Biosciences with a new price targetAnalyst initiated coverage of Alamar Biosciences with a rating of Overweight and set a new price target of $30.00
- ANALYSTBofA Securities initiated coverage on Alamar Biosciences with a new price targetBofA Securities initiated coverage of Alamar Biosciences with a rating of Neutral and set a new price target of $27.00
- ANALYSTTD Cowen initiated coverage on Alamar Biosciences with a new price targetTD Cowen initiated coverage of Alamar Biosciences with a rating of Buy and set a new price target of $30.00
- ANALYSTLeerink Partners initiated coverage on Alamar Biosciences with a new price targetLeerink Partners initiated coverage of Alamar Biosciences with a rating of Outperform and set a new price target of $35.00
- ANALYSTStifel initiated coverage on Alamar Biosciences with a new price targetStifel initiated coverage of Alamar Biosciences with a rating of Buy and set a new price target of $28.00
- SECSEC Form 10-Q filed by Alamar Biosciences Inc.10-Q - Alamar Biosciences, Inc. (0002104204) (Filer)
- SECAlamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alamar Biosciences, Inc. (0002104204) (Filer)
- PRAlamar Biosciences Reports First Quarter 2026 Financial ResultsFREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.Raised approximately $220 million in gross proceeds from our initial public offering in April 2026. "We began 2026 with a record quarter
- PRAlamar Biosciences to Participate in BofA Securities 2026 Healthcare ConferenceFREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada. Alamar Biosciences' management is scheduled to present on Tuesday, May 12, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the "Investors" section of the company website at investors.alamarbio.com. About Alamar Biosciences, Inc. Alamar is a life sciences company dedicated to powering Precision Proteomics to enab
- PRAlamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026. Alamar Biosciences plans to host and webcast its first earnings conference call as a public company in August 2026 to report second quarter 2026 financial results. About Alamar Biosciences, Inc. Alamar is a life sciences company dedicated to powering Precision Proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's
- SECSEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)
- SECSEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)
- INSIDERSEC Form 4 filed by Qiming Corporate Gp Vi, Ltd.4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- SECSEC Form EFFECT filed by Alamar Biosciences Inc.EFFECT - Alamar Biosciences, Inc. (0002104204) (Filer)
- INSIDERSEC Form 4 filed by Illumina Innovation Fund Ii Gp, L.L.C.4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERSEC Form 4 filed by Chambers Rebecca4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERSEC Form 4 filed by Witney Frank4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERSEC Form 4 filed by White Timothy Ogden4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
ALMR FAQ
6 questionsWhere does ALMR stock trade?
Alamar Biosciences Inc. (ALMR) is listed on NASDAQ.What sector and industry is ALMR in?
Alamar Biosciences Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Alamar Biosciences Inc. go public?
Alamar Biosciences Inc. (ALMR) completed its IPO in 2026.What are analysts saying about ALMR?
Alamar Biosciences Inc. has had 5 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $3000.00 price target on 2026-05-12. Recent price targets range from $2700.00 to $3500.00.What companies are similar to ALMR?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare ALMR side-by-side with any of them on Quantisnow.How can I track ALMR on Quantisnow?
Quantisnow aggregates Alamar Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALMR to receive live email and push alerts on every new disclosure.